All News
Guselkumab in Psoriatic Arthritis
D1 and D2 trials compared guselkumab vs placebo in patients with active PsA, with the major difference between the two being that only biologic-naïve patients were enrolled in the D2 trial. Today, we discuss three abstracts presented at ACR 2021 that expand on that work with an additional year of data.
Read Article
In support of early dx and tx in AS! Study of AS pts treated with GLM: those w/ early dz showed sign/symptom improvement compared to those w/ late dz. IV GLM better overall regardless of dz duration. Abs 0912 #ACR21 #RheumNow @RheumNow https://t.co/S2L97c7oQO https://t.co/XXpveRwwmQ
Dr. Rachel Tate uptoTate ( View Tweet)
Phase 3 observational extension study of Lorecivivint, intra-articular CLK/DYRK inhibitor that modulates Wnt and inflammatory pathways. Safety and tolerability. Efficacy at 6 and 12 month, but at 18month it disappeared @RheumNow #ACR21 abst#0729 https://t.co/9ycbVGKkmy
Bella Mehta bella_mehta ( View Tweet)
Abst0919 #ACR21 @RheumNow Phase III COAST-V 52W (PBO)-controlled study examined the efficacy of IXE in pts with active AS. SF-36 bodily pain, improvements were observed at W16 & W52 whether inflammation was controlled or not per MRI, CRP, MRI+CRP, or BASDAI 5/6. https://t.co/uHLwFctzPr
Olga Petryna DrPetryna ( View Tweet)
"The strongest single predictor of both telemedicine and electronic patient portal use was English language preference." Improving access needs to include barrier awareness of SES and communication issues. Abs 0615 #ACR21 #RheumNow #ACRbest @RheumNow https://t.co/ug4xdWbnST https://t.co/t9DsAVm8aQ
Dr. Rachel Tate uptoTate ( View Tweet)
#ACR21 Abs#0834: CorEvitas Registry TNFi vs IL-6 in RA
⭐️IL6 pts older, longer h/o RA, higher CDAI, more prior Rx
▶️ No difference in outcomes bw IL6 and TNFi (monotherapy or combo w MTX).
▶️1/3 of pts achieved LDA
Limits: real-world, unblinded
https://t.co/AJtzeMuj1T @Rheumnow
Links:
Eric Dein ericdeinmd ( View Tweet)
Single Intraarticular Canakinumab in Knee OA - 18-week randomized, double-blind, double-dummy Placebo and naproxen-controlled - effect no different than Placebo. Some efficacy in subgroup with high hsCRP. Need for subtypes in OA @rheumnow #ACR21 #abst0728 https://t.co/YlKTMf56wF
Bella Mehta bella_mehta ( View Tweet)
Novel treatment options for Giant Cell Arteritis
At this #ACR21, encouraging data will be presented on two such potential options for GCA.
https://t.co/gyVXHDRXrj
@RichardPAConway https://t.co/V2Fg8kCjWy
Links:
Dr. John Cush RheumNow ( View Tweet)
Great Hench Lecture from Peggy Crow at HSS! From LE Cell to Interferon: Deconstructing Lupus Pathogenesis
#ACR21 https://t.co/rUxiwKGFqm https://t.co/af2PKrFBv3
Links:
Dr. John Cush RheumNow ( View Tweet)
Obesity does not affect #SLE disease activity despite persistent ⬆️in CRP. From Toronto #lupus database #ACR21 abst#0864 @RheumNow https://t.co/4ZpAMaU0jk
Janet Pope Janetbirdope ( View Tweet)
Results from @rheum_covid on #COVID19 outcomes in patients with #vasculitis #Abs0952 #ACR21
👉🏼~1000 pts
👉🏼Severe outcomes esp in #GCA and #AAV
👉🏼Older age, comorbidities, disease activity, high-dose steroids assoc with worse outcomes
@RheumNow
https://t.co/e2UlgDpyjw https://t.co/skoTKVYbEL
Mrinalini Dey DrMiniDey ( View Tweet)
Dr Jin @SeoyoungCKim population-based study on predictors of switching after 1st line TNFi use. 22% switch, most to 2nd TNFi.👩, prior steroid use predicted change, other autoimmune disease and vit D use negative predictors. Abstr#579 #ACR21 @RheumNow https://t.co/YpZ5rGBiod
Richard Conway RichardPAConway ( View Tweet)
‘Cool’ explanation for #COVID toes. Type I IFN response can drive perniosis. Great session of cases from Len Calabrese & Jack Cush @RheumNow #ACR21 7S001 usual suspects https://t.co/v8IX2xxOZ7
Janet Pope Janetbirdope ( View Tweet)
2 year extension study on Upadacitinib in active AS
⭐️ASAS40 response maintained
⭐️MRI SPARCC scores decreased and maintained
⭐️infections most common AE
⭐️NO MACE, lymphoma, skin cancer, GI perforations
Abs#924
#ACR21 #ACRBest
@RheumNow
https://t.co/725IRAOgtW https://t.co/FVUoCi6aoQ
Robert B Chao, MD doctorRBC ( View Tweet)
Jorge Plutzky, cardiologist perspective on RA at #ACR21
⭐️CANTOS: Canakinumab for MACE shows ⬇️ inflammation, no change in LDL. Improvement in MACE events
▶️Plutzky: "Proof of concept study"
@Rheumnow https://t.co/Xi9ZHxMtmu
Eric Dein ericdeinmd ( View Tweet)
Another benefit of DMARD use in RA. Dr Sood reports lower risk of long term opioid use. Very important given the harm of opioids Abstr#587 #ACR21 @RheumNow https://t.co/d1Dharf5jZ
Richard Conway RichardPAConway ( View Tweet)
We need to control not only inflammation but also lipids levels in our patients w/ IA! Dr Plutzky brilliantly talking us through CV risk and RA showing data on how poor LDL control and coronary microvascular dysfunction lead to worse long term CV outcomes.
@RheumNow #ACR21 https://t.co/o6GWHDai5z
Aurelie Najm AurelieRheumo ( View Tweet)
@MilenaGianfran @JYazdanyMD present on differential effects of biologics on CDAI in obese patients with rheumatoid arthritis. Abatacept better than TNFi in obese. Tocilizumab better than TNFi in non-obese. Abstr#0588 #ACR21 @RheumNow #ACRBest https://t.co/UcEpMAmNVw
Richard Conway RichardPAConway ( View Tweet)
Attaining low disease activity in #SLE ⬇️ mortality! More time in LLDAS = #lupus low disease activity state = ⬆️survival in >4000 pts with SLE. Also + was clinical remission on treatment CROT. Treat to a target has come to SLE @RheumNow #ACR21 abst0865 #ACRBest #RheumPix https://t.co/8ld8oncFRR
Janet Pope Janetbirdope ( View Tweet)
The drug retention for SEC and TNFi was similar in this RW study of 279 patients (TNFi 178, SEC 101).In subgroups analyses, age, BASDAI at diagnosis and BMI did not favour any group @RheumNow #ACR21 Abst#0911 https://t.co/g1tIy1qMX1 https://t.co/LHZMxMlzIB
Dr. Antoni Chan synovialjoints ( View Tweet)